Tag:

Alzheimer's

Latest Headlines

Latest Headlines

J&J pumps more cash into California startup with eye-imaging test for Alzheimer's

Johnson & Johnson sees big things ahead for California's NeuroVision, so it's expanding its partnership with the company. The move gives NeuroVision a boost as it looks to grab a bigger piece of the market for its Alzheimer's eye-imaging diagnostic.

Biogen backs Rodin's Alzheimer's efforts in a $500M deal

Rodin Therapeutics recruited Biogen to help advance its novel approach to Alzheimer's disease in a pairing that could end with the Atlas Venture company getting bought for $485 million.

Singapore's TauRx mulls Nasdaq IPO and sees a future for Alzheimer's treatment

Singapore-based TauRx is expected to complete global Phase III trials this year for its Alzheimer's candidate, tau aggregation inhibitor LMTX, that will either start a new chapter in treatment or join a long list of flops.

Big Pharma backs $100M dementia R&D fund

Some of the top companies in Big Pharma have contributed to a $100 million venture fund that will be invested in R&D aimed at finding new therapies for Alzheimer's.

Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects

Healthcare informatics company Advera Health Analytics delved into FDA postmarketing safety reports and compiled data on Alzheimer's drugs. The firm found that Novartis' Exelon patch, Allergan's Namenda and Eisai's Aricept showed more reports of serious side effects than other drugs, with safety issues ranging from convulsions and gastrointestinal hemorrhage to respiratory failure and sudden death.

Nestlé seeks to deploy its diagnostics device for the early detection of Alzheimer's

Tech titans like Google, Samsung and Apple have clear med tech ambitions. Now a food giant is trying to grab a slice of the pie. The Nestlé Institute of Health Sciences SA seeks to deploy its proprietary diagnostic technology platform to develop an assay for the early detection of Alzheimer's.

Gene variant linked to a 10-year delay in Alzheimer's onset

By studying a group of outliers in a Colombian family known for the prevalence of early-onset Alzheimer's, investigators at UC Santa Barbara believe they may have fingered a new drug target that could delay the disease by a decade or more.

Lilly's CEO keeps faith in the pipeline as biotech gets 'too expensive'

Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.

New York startup trots out video game-like screening device for Alzheimer's

As scientists zero in on quick, inexpensive ways to screen for Alzheimer's, a New York startup is developing a video game-like tool for catching early signs of the disease.

Boehringer dumps its Alzheimer's BACE pact with Vitae

Shares of Vitae Pharmaceuticals dropped 5% this morning after the biotech reported that Boehringer Ingelheim had decided to dump its collaboration on a new BACE program for Alzheimer's.